Publication planning is the strategic discipline of deciding what clinical evidence to publish, where, when and how. A publication plan is not a wish list of manuscripts — it is a strategic document that maps the company's clinical data to the journals, congresses and audiences that will have the most scientific impact. Done well, a publication plan ensures that the scientific community has access to the full body of evidence, presented transparently and in a logical sequence.

The foundation of a publication plan is the data inventory. Before deciding what to publish, the writer must catalogue all available data: completed trials, ongoing studies, post-hoc analyses, real-world evidence, health-economic analyses, and any relevant nonclinical data. Each data set is then assessed for its scientific merit, audience relevance and strategic importance.

The plan must address the publication sequence. The primary publication of a pivotal trial typically comes first, followed by secondary analyses (subgroup analyses, quality-of-life data, long-term follow-up), then pooled analyses and real-world evidence. This sequence builds the evidence base methodically — each publication adds to the narrative established by the previous ones.

GPP (currently GPP 2022) is the industry standard for responsible, ethical publication of company-sponsored research. It covers authorship criteria, transparency, trial registration, and the disclosure of sponsor involvement. Medical writers who work on publications must know GPP thoroughly — violations can result in retractions, regulatory sanctions, and reputational damage.

Key GPP principles include: all company-sponsored trials should be published regardless of outcome (no selective publication of positive results only); authorship must follow ICMJE criteria (authors must have made substantial contributions, not just hold an organisational title); professional medical writers should be acknowledged; and the sponsor's involvement in the design, conduct and reporting of the study must be transparent.

GPP also addresses the contentious issue of ghost writing. A ghostwritten publication is one where a professional writer contributed substantially but is not acknowledged. GPP prohibits ghost writing unequivocally. The medical writer may draft the manuscript, but they must be listed as a named contributor or acknowledged, and the listed authors must have made substantive intellectual contributions to the work.

The primary publication of a pivotal trial is the single most important deliverable in a medical communications programme. It establishes the evidence base in the peer-reviewed literature, provides the citable reference for all subsequent communications, and shapes how the medical community perceives the clinical evidence. A poorly written primary publication — one that overstates the results, omits important safety data, or uses misleading statistics — can undermine the product's scientific credibility irreparably.

Writing a primary publication requires mastery of the IMRAD format (Introduction, Methods, Results, and Discussion) as applied to a randomised clinical trial. Each section has specific conventions, and top-tier journals enforce them rigorously. The writer must also follow the CONSORT (Consolidated Standards of Reporting Trials) checklist, which specifies the information that must be included in a trial report. CONSORT compliance is a requirement for most major journals.

The CONSORT 2010 statement provides a 25-item checklist for reporting parallel-group randomised trials. Extensions exist for cluster trials, non-inferiority trials, pragmatic trials, and other designs. The medical writer must know which items are mandatory and where they belong in the manuscript.

Key CONSORT items that writers frequently miss include: a structured flow diagram showing enrolment, allocation, follow-up and analysis (CONSORT diagram); pre-specified primary and secondary outcomes with clear definitions of how they were measured; the method of randomisation, including the mechanism of allocation concealment; the type of blinding (participants, care providers, outcome assessors) and a description of the similarity of interventions; all pre-specified analyses including subgroup analyses; and a complete account of all important harms. The last point is critical — a primary publication that emphasises efficacy and underreports safety will be viewed with suspicion by reviewers, agencies and the medical community.

The results section of a primary publication follows a specific order: participant flow (CONSORT diagram), baseline demographics and clinical characteristics, primary outcome, secondary outcomes, subgroup analyses, and safety. Each result must include the point estimate, the measure of precision (95% confidence interval), and the pre-specified statistical test. P-values are reported for pre-specified hypothesis tests; exploratory analyses should use language that reflects their hypothesis-generating nature.

A critical error in publication writing is presenting post-hoc analyses as if they were pre-specified. If a subgroup analysis was not in the statistical analysis plan, it must be labelled as post-hoc, and the language must reflect the exploratory nature: "The post-hoc analysis suggested a potential trend..." not "The analysis demonstrated a significant benefit in..."

Medical congresses are the primary venue for disseminating new clinical data to the specialist community. A well-executed congress programme can shape scientific discourse, position a compound in the therapeutic landscape, and generate media coverage that reaches prescribers worldwide. The medical writer's role encompasses abstract preparation, poster development, slide creation, speaker training, and post-congress activities.

Abstract writing for congresses is a distinct skill from manuscript writing. Abstracts are constrained by strict word counts (typically 250-400 words), must include structured sections (background, methods, results, conclusions), and must present results that are final — congress committees reject abstracts based on interim analyses unless specifically invited. The abstract must tell a complete story in the allotted space, which requires ruthless prioritisation of what to include.

A scientific poster is a visual medium, not a scaled-down manuscript. The most common error in poster design is cramming manuscript-length text onto a 48×72 inch board. An effective poster uses data visualisation — forest plots, Kaplan-Meier curves, bar charts — as the primary communication tool, with text limited to context, methods summary, and key conclusions.

The writer must understand the visual hierarchy of a poster: the title and conclusion are read from three metres away; the figures are examined from one metre; the methods and fine print are read from 50 centimetres. Design every element for its reading distance. This means large fonts for the title (≥85 pt), medium fonts for section headers (≥36 pt), readable fonts for body text (≥24 pt), and clear, high-contrast figures.

Developing an oral presentation for a congress is more than creating slides. The medical writer creates the slide deck, the speaker notes, and often trains the presenter. The slides must tell a visual story — each slide should make one point, supported by one figure or table. A common error is producing text-heavy slides that the speaker reads verbatim. If the audience can read the slide faster than the speaker can present it, the slide has too much text.

The writer must also prepare for the Q&A. Congress presentations of pivotal data will attract challenging questions from the audience. Anticipating these questions — typically about limitations, alternative explanations for the results, and comparisons with competitors — and preparing concise, data-based responses is part of the writer's role.

A scientific platform (also called a medical strategy or scientific narrative) is the foundational document that defines how a company talks about its product in scientific and medical contexts. It is not a promotional positioning statement — it is an evidence-based framework that maps the clinical data to the scientific questions the medical community is asking.

The platform typically includes: the disease background (epidemiology, pathophysiology, burden of disease); the current treatment landscape (existing therapies, their limitations, and the unmet medical need); the product's mechanism of action and pharmacology; the clinical evidence (efficacy, safety, and patient-reported outcomes); the product's place in the treatment algorithm; and the key scientific messages, each linked to its supporting evidence.

Every medical communications deliverable — from a congress poster to a medical information letter — should trace back to the scientific platform. This ensures consistency across all channels and audiences. When a new data readout occurs, the platform is updated, and all downstream materials are refreshed to reflect the new evidence.

A key scientific message is a concise, evidence-supported statement about the product's clinical profile. Unlike a promotional claim, a scientific message presents data in a balanced way — it may include both the efficacy finding and its limitations. For example, a promotional claim might be "Drug X reduces HbA1c more than Drug Y." A scientific message might be "In the head-to-head COMPARE trial, Drug X demonstrated a statistically significant greater reduction in HbA1c compared with Drug Y (−1.2% vs −0.8%, p<0.001) over 52 weeks; the incidence of hypoglycaemia was similar between groups."

Each key message should be: evidence-based (linked to specific studies and data), balanced (including relevant safety context), differentiated (highlighting what is unique about this product's evidence), and audience-appropriate (adapted for HCPs, payers or patients as needed).

Advisory boards are structured meetings where a sponsor convenes a small group of external experts (typically 8-15) to obtain their scientific advice on specific questions. Unlike promotional speaker programmes, advisory boards are designed to generate input from the advisors — the information flows from the experts to the company, not the other way around. This distinction is critical: a regulatory authority or compliance team will scrutinise whether an advisory board had a legitimate scientific purpose or was a disguised promotional event.

The medical writer's role in advisory boards includes: developing the scientific agenda (the specific questions the company needs answered), creating pre-read materials (background data, published evidence, discussion frameworks), writing discussion guides (structured questions to guide the conversation), and producing the post-meeting report (a comprehensive summary of the advisors' input and its implications for the medical strategy).

Medical education encompasses continuing medical education (CME), certified education programmes, and non-certified educational initiatives. The key distinction is whether the programme is certified by an accrediting body (such as ACCME in the US or EACCME in Europe), which imposes strict requirements on content independence, faculty selection, and disclosure of commercial support.

For certified CME, the content must be balanced, evidence-based, and free from commercial bias. The faculty must be independent of the sponsor. The sponsor may provide an educational grant but cannot influence the content. The medical writer who develops CME content must understand these requirements and ensure that the materials meet the accrediting body's standards — not the sponsor's promotional objectives.

Non-certified medical education has more flexibility in content and speaker selection but still must comply with the relevant promotional regulations. The line between education and promotion is policed by regulatory agencies, and a programme that claims to be educational but presents only the sponsor's product in a favourable light will be viewed as disguised promotion.

Payer communications is the branch of medical communications that addresses health technology assessment bodies, formulary committees, insurance companies and government healthcare systems. These audiences make decisions about whether a drug will be reimbursed — and at what price — based on evidence of clinical value, cost-effectiveness and budget impact.

The medical writer who works in payer communications must understand health economics: concepts like quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs), budget impact models, indirect treatment comparisons (ITCs), and network meta-analyses (NMAs). These are not abstract concepts — they determine whether patients in an entire healthcare system will have access to a new treatment.

A value dossier (also called an AMCP dossier in the US, or a health technology assessment submission in the EU/UK) is a comprehensive document that presents the clinical, economic and humanistic evidence supporting a product's value. The structure follows established templates: the AMCP Format for Formulary Submissions in the US, and HTA body-specific templates (NICE in the UK, G-BA in Germany, HAS in France) in Europe.

The value dossier typically includes: the disease and treatment background, the clinical evidence (efficacy, safety, comparative effectiveness), the economic evidence (cost-effectiveness analysis, budget impact analysis), patient-reported outcomes, and a summary of the product's overall value proposition. The evidence must be presented transparently, with full disclosure of assumptions, limitations and sensitivity analyses.

A critical component of the value dossier is the indirect treatment comparison or network meta-analysis. When head-to-head trials against all relevant comparators are not available — which is the norm — the writer must present ITC or NMA results that estimate comparative effectiveness across the treatment landscape. These analyses have specific methodological requirements and limitations that the writer must present honestly.

Risk communication is the branch of medical communications that deals with safety signals, product withdrawals, regulatory safety actions, and crisis management. It is the highest-stakes area of med comms — the language used in a Dear Healthcare Professional letter, a label update, or a media statement can affect prescribing behaviour, patient safety and public trust.

Effective risk communication follows specific principles: it is timely (the first response sets the narrative), accurate (errors in safety communications are catastrophic), balanced (acknowledging the risk without causing unnecessary alarm), actionable (telling the recipient what to do), and transparent (disclosing what is known, what is not known, and what is being done to find out).

The medical writer in a risk communication scenario must work under extreme time pressure while maintaining the highest standards of accuracy. A Dear Healthcare Professional (DHCP) letter — also called a Dear Doctor letter — typically must be drafted, reviewed, approved and distributed within days of a regulatory request. The writer must distil complex safety data into clear, actionable language that a busy clinician can understand and act on immediately.

The DHCP letter is the primary vehicle for communicating important safety information to prescribers. It follows a standard structure: a header identifying it as an important safety communication (often with the product name and the nature of the risk), the new safety information, the recommended actions for prescribers, contact information for medical inquiries, and the regulatory agency's role. The tone must be urgent but not alarmist — the goal is to change prescribing behaviour, not to cause panic.

Key elements of an effective DHCP letter include: a clear subject line that names the product and the risk; a concise first paragraph that states what has changed and why the letter is being sent; the clinical details of the safety signal (what was observed, in how many patients, over what time period); the recommended monitoring or prescribing changes; and where to report additional cases.

Digital channels have transformed medical communications. Healthcare professionals increasingly access medical information through online platforms, social media, and mobile applications. Patients research their conditions, treatments, and clinical trials online. Payers use digital tools to evaluate cost-effectiveness data. The medical communicator must understand how to use these channels effectively while maintaining regulatory compliance.

The regulatory framework for digital medical communications is still evolving. The FDA has issued guidance on internet and social media promotion, but many questions remain unresolved. Key principles include: all digital content is subject to the same regulatory requirements as print content; social media posts that mention a product by name must include fair balance (risk information alongside benefit claims); unsolicited requests for medical information received through digital channels may be answered with off-label information under specific conditions; and user-generated content on company-sponsored platforms creates monitoring and reporting obligations.

A medical information website serves as the company's digital presence for scientific and medical content. Unlike a promotional website, a medical information site presents clinical data, prescribing information, safety data, and educational resources without promotional framing. The design must clearly separate medical from commercial content, and the content must be regularly updated to reflect the current evidence.

Key considerations for medical information websites include: audience segmentation (HCP-only content should be behind a professional verification gate; patient content should meet health literacy standards); content governance (who reviews and approves content, how often is it updated, and how are outdated materials archived); adverse event reporting (the site must provide a mechanism for reporting adverse events, and the company must monitor the site for potential safety reports); and regulatory compliance (all content must be consistent with the approved labelling).

Social media presents unique challenges for medical communications. The character limits of platforms like Twitter (X) make it difficult to include fair balance alongside benefit statements. The real-time nature of social media means that off-label discussions, adverse event reports, and misinformation can emerge rapidly. The viral nature of social media means that a single poorly worded post can reach millions of healthcare professionals and patients within hours.

Effective social media strategy for medical communications requires: clear internal policies on what can and cannot be posted; a rapid response process for addressing misinformation or adverse event reports; a monitoring system that captures relevant conversations; and training for anyone who posts on behalf of the company. The medical writer may be involved in developing social media content, reviewing posts for compliance, and drafting responses to medical inquiries received through social channels.

An integrated medical communications plan (IMCP) is the strategic document that coordinates all medical communications activities across channels, audiences and timelines. It is the master plan that ensures every publication, congress presentation, advisory board, medical education programme, payer dossier and digital initiative works together to build a coherent scientific narrative.

The IMCP typically covers a 12-36 month period and includes: the strategic context (disease landscape, competitive environment, regulatory timeline), the core scientific messages (from the scientific platform), the audience strategy (who needs to hear what, and when), the channel strategy (which channels reach which audiences most effectively), the activity timeline (a Gantt chart showing all planned activities and their dependencies), the resource plan (internal writers, agency partners, budgets), and the measurement framework (how success is defined and tracked).

Effective audience mapping goes beyond the simple categories of "HCPs, payers, patients." It identifies specific segments within each audience and the channels that reach them most effectively. For HCPs, this means distinguishing between early adopters (who attend congresses and read primary literature), mainstream prescribers (who rely on guidelines and peer influence), and specialists in adjacent fields (who may refer patients). For payers, it means distinguishing between national HTA bodies, regional formulary committees, and individual hospital pharmacy and therapeutics committees.

Channel strategy matches each audience segment to its preferred information channels. Early-adopter HCPs are reached through primary publications and congress presentations. Mainstream prescribers are influenced by guidelines, CME programmes, and peer recommendations. Payers require value dossiers, budget impact analyses, and real-world evidence. Patients access information through patient education materials, disease awareness campaigns, and online resources.

Measuring the impact of medical communications is both essential and challenging. Traditional metrics — number of publications, congress presentations, advisory boards — measure activity, not impact. More meaningful metrics include: publication impact (citations, altmetric scores, downloads), awareness and knowledge change (measured through surveys before and after specific activities), guideline inclusion (whether the product is mentioned in treatment guidelines), formulary access (the proportion of target markets where the product is on formulary), and prescriber behaviour change (measured through prescription data analysis).

The challenge is attribution — it is difficult to isolate the impact of a single publication or advisory board from the many other factors that influence prescribing behaviour. The best measurement frameworks use a combination of leading indicators (awareness, knowledge, stated intent) and lagging indicators (prescriptions, market share) to build a picture of communications effectiveness over time.

Patient communications is the discipline of creating medical information for patients, caregivers and the public. It requires a fundamentally different skill set from writing for healthcare professionals. The audience may have no medical training, may be in emotional distress, may have limited health literacy, and may be making life-altering decisions based on what they read. The writer's responsibility is to be accurate, clear, compassionate and empowering — never paternalistic, alarmist or dismissive.

Health literacy is a central concern. Research consistently shows that a large proportion of adults have limited health literacy — they struggle with medical terminology, numerical concepts (risk percentages, dosing), and the structure of healthcare systems. Patient materials must be written at a reading level appropriate for the target audience (typically 6th-8th grade reading level in the US), use plain language, and present numerical information in formats that aid comprehension (such as natural frequencies: "5 out of 100 people" rather than "5%").

Plain language is not about dumbing down — it is about clear communication. The principles include: use short sentences (15-20 words average); use active voice; use common words instead of medical jargon (but define technical terms when they are unavoidable); use headings and bullet points to break up dense text; and present the most important information first.

Visual design is equally important. Patient materials should use readable fonts (12-14 pt minimum), adequate white space, clear visual hierarchy, and culturally appropriate images. Infographics can be highly effective for presenting risk-benefit information, treatment timelines, and decision-support tools. The writer must collaborate with designers to ensure that the visual presentation supports the written content.

Testing patient materials with the target audience is best practice. What seems clear to a medical writer may be confusing to a patient. Methods include readability formulas (Flesch-Kincaid, SMOG), cognitive interviews (where patients read the material aloud and explain their understanding), and usability testing (where patients use the material to complete a task, such as finding the dose information).

This capstone module challenges you to synthesise everything you have learned into a comprehensive medical communications strategy. The strategy must address multiple audiences (HCPs, payers, patients), multiple channels (publications, congresses, digital, education), multiple phases (pre-approval, launch, post-launch), and multiple regulatory environments (US, EU, rest of world).

A successful strategy starts with three questions: What does the evidence show? Who needs to know? And how will they receive it? The first question is answered by the clinical data and the scientific platform. The second is answered by audience mapping and needs assessment. The third is answered by channel strategy and tactical planning.

Medical communications is not a launch activity — it spans the entire product lifecycle. Pre-approval communications establish the scientific foundation: publications, congress data presentations, and disease awareness campaigns that educate the community about the unmet need. Launch communications translate the clinical evidence into actionable information for prescribers, payers and patients. Post-launch communications build the evidence base with real-world data, long-term follow-up, and comparative effectiveness studies.

The lifecycle perspective also means planning for challenges. Every product will face competitive threats (new entrants, generic competition), safety signals (post-marketing reports, REMS requirements), and evidence gaps (populations not studied in clinical trials, long-term outcomes). The communications strategy must anticipate these challenges and include contingency plans.

The medical communications professional occupies a position of trust. Healthcare professionals rely on the accuracy and completeness of the information they receive. Patients trust that the materials they read are balanced and honest. Regulatory agencies trust that promotional regulations are being followed. Maintaining this trust requires unwavering commitment to scientific integrity, transparency, and ethical conduct.

This commitment is tested regularly. Commercial pressures may push for more favourable data presentation. Tight timelines may tempt shortcuts in quality control. Competitive dynamics may encourage overstating results or understating risks. The medical communicator's professional identity is defined by the choices made in these moments — choosing accuracy over convenience, balance over spin, and transparency over selective presentation.

The EQUATOR Network maintains over 500 reporting guidelines. In practice, six cover most of what a medical communications writer encounters:

Editors and peer reviewers see the same gaps repeatedly. Knowing what is most often missing lets you catch it before submission:

Since 2005, the ICMJE has required prospective registration of all interventional trials as a condition of publication. Registration means committing — before the first participant is enrolled — to the primary endpoint, the sample size, and the analysis plan. This prevents outcome switching and selective reporting.

Not all text reuse is plagiarism, but all text reuse must be handled correctly:

Image manipulation is the fastest-growing reason for retraction. As a writer, you may not create the figures — but you must know what to check:

Studies consistently find that 25–40% of references in published papers contain at least one error, and 5–10% have errors serious enough to make the reference unverifiable. As the writer who compiles the reference list, you can prevent most of these.

Before recommending or agreeing to submit to any journal, run these five checks:

Published errors are inevitable. How they are handled separates good-faith science from misconduct: